Skip to search formSkip to main contentSkip to account menu

rolapitant hydrochloride

Known as: Rolapitant Monohydrochloride Monohydrate, 1,7-Diazaspiro(4.5)decan-2-one, 8-(((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-, Monohydrochloride, Monohydrate, (5S,8S)-, Rolapitant HCl 
The hydrochloride salt form of rolapitant, an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor) antagonist with… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
SummaryRolapitant is a neurokinin-1 receptor antagonist that is approved in combination with other antiemetic agents in adults… 
2018
2018
Prophylaxis or therapy with a combination of a neurokinin 1 (NK-1) receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA… 
2018
2018
Prophylaxis or therapy with a combination of a neurokinin 1 (NK-1) receptor antagonist (RA), a 5-hydroxytryptamine- 3 (5-HT3) RA… 
Review
2017
Review
2017
Knowledge of the involvement of the neurokinin substance P in emesis has led to the development of the neurokinin-1 receptor… 
Review
2016
Review
2016
  • R. Navari
  • Drugs of Today
  • 2016
  • Corpus ID: 4836599
Chemotherapy-induced nausea and vomiting (CINV) is a significant clinical issue which affects patients' quality of life as well… 
2016
2016
Chemotherapiebedingte Übelkeit und Erbrechen (CINV) gefährden den Erfolg onkologischer Therapien. Rolapitant ist ein neuartiger…